Celgene

Roche and Celgene set for battle in acute myelogenous leukaemia
Roche and Celgene set for battle in acute myelogenous leukaemia
EP Vantage
Celgene
Roche
AML
acute myeloid leukemia
CC-486
Venclexta
Flag link:
Celgene's AML drug clears late-stage test
Celgene's AML drug clears late-stage test
Endpoints
Celgene
AML
CC-486
acute myeloid leukemia
Flag link:
Celgene's phase 3 AML test chalks up a win
Celgene's phase 3 AML test chalks up a win
Fierce Biotech
Celgene
acute myeloid leukemia
CC-486
clinical trials
Flag link:
[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug
[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug
Motley Fool
FTC
Amgen
Celgene
Bristol-Myers Squibb
M&A
Otezla
Flag link:
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
Endpoints
Roche
Tecentriq
FDA
Europe
Celgene
Abraxane
triple negative breast cancer
Flag link:
Mark Your Calendar For These September PDUFA Dates
Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
FDA
Roche
Celgene
Tecentriq
Xeris Pharmaceuticals
Gvoke
Ardelyx
tenapanor
Merck
Pifeltro
Delstrigo
Novo Nordisk
semaglutide
JNJ
Genmab
daratumumab
Invokana
Flag link:
Yes, Amgen overpaid for Otezla—but that doesn't make it a mistake: analysts
Yes, Amgen overpaid for Otezla—but that doesn't make it a mistake: analysts
Fierce Pharma
Amgen
Otezla
Enbrel
drug reps
M&A
Celgene
Flag link:
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
Flag link:
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Xconomy
Celgene
cell therapies
drug development
Immatics
cancer
Flag link:
Six burning Otezla questions
Six burning Otezla questions
EP Vantage
Celgene
Otezla
Amgen
drug pricing
FTC
Tyk2
Bristol-Myers Squibb
Flag link:
Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps
Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps
Endpoints
Bristol-Myers Squibb
Celgene
Presage Biosciences
Phase 0 testing
drug development
Flag link:
Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win
Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win
Motley Fool
Amgen
Celgene
Otzela
Flag link:
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Stat
Amgen
Otezla
Celgene
M&A
Bristol-Myers Squibb
psoriasis
Flag link:
How Big Is Celgene's Latest Good News?
How Big Is Celgene's Latest Good News?
Motley Fool
Celgene
Otezla
Revlimid
Inrebic
Flag link:
Celgene wins approval for drug key to Bristol buyout
Celgene wins approval for drug key to Bristol buyout
Biopharma Dive
Celgene
FDA
Inrebic
myelofibrosis
M&A
Bristol-Myers Squibb
Flag link:
Celgene Continues Growing While Waiting for its Acquisition to Close
Celgene Continues Growing While Waiting for its Acquisition to Close
Motley Fool
Celgene
earnings
M&A
Bristol-Myers Squibb
Flag link:
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
Flag link:
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements
Fierce Pharma
Celgene
Bristol-Myers Squibb
antitrust
Flag link:
Celgene Offers Beat-And-Raise As Bristol Merger Looms Closer
Celgene Offers Beat-And-Raise As Bristol Merger Looms Closer
Investors Business Daily
Celgene
earnings
M&A
Bristol-Myers Squibb
Flag link:
Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says
Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
drug pricing
Giovanni Caforio
Flag link:

Pages